Skip to main content
. Author manuscript; available in PMC: 2018 Nov 15.
Published in final edited form as: J Immunol. 2017 Oct 9;199(10):3437–3452. doi: 10.4049/jimmunol.1700953

Figure 6. Shared CDR3 features between TRAV29 and TRAV24 Gag293-specific clonotypes.

Figure 6

(A) Frequency of TRAV29 expression in Gag293-specific clonotypes from vaccinees (week 10, red, n=5; week 38, light blue, n=3), HIV controllers (HIC, dark blue, n=8) and treated patients (HAART, green, n=8). The frequency of TRAV29 in the total clonotypic repertoire of healthy donors (HD, clear circles, n=7) is shown for comparison.

(B) Pie charts depicting the distribution of TRAJ gene usage in Gag293-specific TRAV24 (top) or TRAV29 (right) sequences from ADVAX recipients. The dominant J genes shared between the TRAV24 and TRAV29 repertoires are colored in red and blue, while other amplified J genes (>10%) are shown in yellow. Number of sequences analyzed: ADVAX TRAV29: 359; ADVAX TRAV24: 473.